Get the Stockscreener App
2.24
11.51%
-0.28
Transcode Therapeutics Inc stock is traded at $2.24, with a volume of 575.19K.
It is down -11.51% in the last 24 hours and down -77.57% over the past month.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
See More
Previous Close:
$2.52
Open:
$2.52
24h Volume:
575.19K
Relative Volume:
0.36
Market Cap:
$1.75M
Revenue:
-
Net Income/Loss:
$-14.93M
P/E Ratio:
-0.00842
EPS:
-266.137
Net Cash Flow:
$-15.87M
1W Performance:
-72.38%
1M Performance:
-77.57%
6M Performance:
-76.53%
1Y Performance:
-90.37%
1-Day Range:
$2.20
$2.54
1-Week Range:
$2.20
$8.40
52-Week Range:
$2.20
$66.33
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
2.23 | 1.75M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.05 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.71 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
616.78 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.78 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
268.30 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
Transcode Therapeutics stock hits 52-week low at $2.62 By Investing.com - Investing.com South Africa
Transcode Therapeutics stock hits 52-week low at $2.62 - Investing.com
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.37% - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.37% - Investing.com
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.37% - Investing.com UK
TransCode Shareholders Green-Light Warrant Changes: What This Means for RNAZ's Financial Future - StockTitan
Stock market news: China SXT Pharmaceuticals -92.51%, TransCode Therapeutics -37.91% among biggest losers during midday trading - Business Upturn
Learn to Evaluate (RNAZ) using the Charts - Stock Traders Daily
TransCode reports positive phase 1 trial progress for cancer therapy - MSN
(RNAZ) Technical Data - Stock Traders Daily
Clinical Trials News Live Feed - StockTitan
RNAZ’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
The -45.19% Simple Moving Average of TransCode Therapeutics Inc’s (RNAZ) Stock in the Past 200 Days - The News Heater
The Impact of Market Fluctuations on ChargePoint Holdings Inc’s (CHPT) Stock - The News Heater
Market Analysts see Helmerich & Payne, Inc [HP] falling to $39. Time to buy? - The DBT News
Wag Group Co [PET] Revenue clocked in at $76.75 million, up 36.38% YTD: What’s Next? - The DBT News
Wall Street Analyst Reiterated Gamestop Corporation [GME]. What else is Wall St. saying - The DBT News
Shoals Technologies Group Inc [SHLS] Stock trading around $4.60 per share: What’s Next? - The DBT News
Ensysce Biosciences (NASDAQ:ENSC) Stock Quotes, Forecast and News Summary - Benzinga
Cronos Group Inc [CRON] fell 0.00% so far this year. What now? - The DBT News
Northern Dynasty Minerals Ltd [NAK] is 26.40% higher this YTD. Is it still time to buy? - The DBT News
For Coupang Inc [CPNG], Analyst sees a rise to $30. What next? - The DBT News
Market Analysts see BBB Foods Inc [TBBB] gaining to $32. Time to buy? - The DBT News
why Borr Drilling Ltd [BORR] is a Good Choice for Investors After New Price Target of $5.23 - The DBT News
American Superconductor Corp [AMSC] Stock trading around $34.24 per share: What’s Next? - The DBT News
Callan JMB Inc [CJMB] gain 54.15% so far this year. What now? - The DBT News
Wall Street Analyst Resumed Equillium Inc [EQ]. What else is Wall St. saying - The DBT News
why Silexion Therapeutics Corp [SLXN] is a Good Choice for Investors After New Price Target of $9.00 - The DBT News
SNDL Inc [SNDL] Is Currently 3.76 above its 200 Period Moving Avg: What Does This Mean? - The DBT News
Envista Holdings Corp [NVST] moved up 5.93: Why It’s Important - The DBT News
2 Top Fintech Stocks to Buy in February - The Globe and Mail
Wall Street Analyst Resumed Lilly[Eli] & Co [LLY]. What else is Wall St. saying - The DBT News
Health In Tech Inc [HIT] Revenue clocked in at $19.80 million, down -0.84% YTD: What’s Next? - The DBT News
AEON Biopharma Inc [AEON] Stock trading around $0.14 per share: What’s Next? - The DBT News
Stocks of TransCode Therapeutics Inc (RNAZ) are poised to climb above their peers - SETE News
TransCode Therapeutics (NASDAQ:RNAZ) Receives Buy Rating from HC Wainwright - Armenian Reporter
Insider Buying: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Director Purchases $103,200.00 in Stock - Armenian Reporter
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Stock market today: Lipella Pharmaceuticals +99.22%, Digital Turbine +68.90% among top gainers in early trading - Business Upturn
Transcode Therapeutics completes Cohort 3 dosing in Phase 1 trial of TTX-MC138 - TipRanks
TransCode reports positive phase 1 trial progress for cancer therapy By Investing.com - Investing.com UK
TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial - PR Newswire
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting - Longview News-Journal
How Is The Market Feeling About TransCode Therapeutics? - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Stock market news: TransCode Therapeutics +133.97%, Diginex +27.49% among top gainers during mid day trading - Business Upturn
Are Investors Keen On Selling Holdings In GSK Plc ADR (NYSE: GSK)? - Stocks Register
Dow Inc (NYSE: DOW) Is A Buzzing Hot Stock - Stocks Register
Stock market today: Sentage Holdings +70.79%, Planet Image International +64.29% among top gainers in early trading - Business Upturn
TransCode Therapeutics Shares Are Surging Today: What's Going On? - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.31%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):